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http://www.biosignaling.com/content/11/1/3RESEARCH Open AccessPlatelet-derived growth factor-induced Akt
phosphorylation requires mTOR/Rictor and
phospholipase C-γ1, whereas S6 phosphorylation
depends on mTOR/Raptor and phospholipase D
Masoud Razmara, Carl-Henrik Heldin and Johan Lennartsson*Abstract
Mammalian target of rapamycin (mTOR) can be found in two multi-protein complexes, i.e. mTORC1 (containing
Raptor) and mTORC2 (containing Rictor). Here, we investigated the mechanisms by which mTORC1 and mTORC2
are activated and their downstream targets in response to platelet-derived growth factor (PDGF)-BB treatment.
Inhibition of phosphatidylinositol 3-kinase (PI3K) inhibited PDGF-BB activation of both mTORC1 and mTORC2. We
found that in Rictor-null mouse embryonic fibroblasts, or after prolonged rapamycin treatment of NIH3T3 cells,
PDGF-BB was not able to promote phosphorylation of Ser473 in the serine/threonine kinase Akt, whereas Thr308
phosphorylation was less affected, suggesting that Ser473 in Akt is phosphorylated in an mTORC2-dependent
manner. This reduction in Akt phosphorylation did not influence the phosphorylation of the S6 protein, a well
established protein downstream of mTORC1. Consistently, triciribine, an inhibitor of the Akt pathway, suppressed
PDGF-BB-induced Akt phosphorylation without having any effect on S6 phosphorylation. Thus, mTORC2 does not
appear to be upstream of mTORC1. We could also demonstrate that in Rictor-null cells the phosphorylation of
phospholipase Cγ1 (PLCγ1) and protein kinase C (PKC) was impaired, and the PKCα protein levels strongly reduced.
Furthermore, interfering with the PLCγ/Ca2+/PKC pathway inhibited PDGF-BB-induced Akt phosphorylation. In
addition, PDGF-BB-induced activation of mTORC1, as measured by phosphorylation of the downstream S6 protein,
was dependent on phospholipase D (PLD). It has been shown that Erk1/2 MAP-kinase directly phosphorylates and
activates mTORC1; in partial agreement with this finding, we found that a Mek1/2 inhibitor delayed S6
phosphorylation in response to PDGF-BB, but it did not block it. Thus, whereas both mTORC1 and mTORC2 are
activated in a PI3K-dependent manner, different additional signaling pathways are needed. mTORC1 is activated in
a PLD-dependent manner and promotes phosphorylation of the S6 protein, whereas mTORC2, in concert with PLCγ
signaling, promotes Akt phosphorylation.
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Platelet-derived growth factor (PDGF) stimulates proli-
feration, migration and survival of mesenchymal cells
and plays a pivotal role during embryonic development
and wound healing [1]. The biologically active form of
PDGF consists of disulphide-linked dimers, PDGF-AA,
-AB, -BB, -CC and –DD, which bind to two structurally
similar tyrosine kinase receptors, i.e. PDGFRα and* Correspondence: Johan.Lennartsson@LICR.uu.se
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reproduction in any medium, provided the orPDGFRβ [2,3]. PDGFRα binds all PDGF chains except
PDGF-D, whereas PDGFRβ interacts only with PDGF
B- and D-chains. The binding of the bivalent ligand induces
dimerization and activation of PDGFRs, leading to auto-
phosphorylation of tyrosine residues in the intracellular re-
gion [2]. Thereby, several signal transduction pathways are
initiated, including phosphatidylinositol 3-kinase (PI3K),
the Src tyrosine kinase, phospholipase Cγ (PLC), and se-
veral mitogen-activated protein (MAP) kinase cascades.
mTOR is the mammalian ortholog of the yeast serine/
threonine kinase TOR which is involved in the regulationl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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tion, cell growth and proliferation, ribosome biogenesis,
transcription and cytoskeletal reorganization [4]. Dysregu-
lation of mTOR signaling is frequently seen in cancer and
has attracted attention as a therapeutic target [5,6]. mTOR
is functional in two distinct complexes, namely mTORC1
and mTORC2 [7]. mTORC1 activity is controlled by the
G-protein Rheb; Rheb-GTP promotes mTORC1 activity
and the tuberous sclerosis complex 1/2 (TSC1/2) acts as a
GTPase activating protein for Rheb, consequently inhi-
biting mTORC1 activity [8]. Generally, mTORC1 is
described as being activated by growth factors through
Akt-mediated phosphorylation which inactivates the
TSC1/2 complex [8-10]. In addition, the TSC1/2 complex
can also be phosphorylated and inhibited by AMPK, thus
allowing the cellular energy status to impact mTORC1
activity [11]. mTORC1 is a rapamycin-sensitive complex,
and includes the proteins Raptor (regulatory-associated
protein of mTOR), mLST8, PRAS40 and Deptor [12].
Raptor acts as a scaffold and thereby controls mTORC1
activity. Established functions for mTORC1 are to phos-
phorylate 4EBP1 and activate S6-kinase, which in turn
phosphorylates the S6 protein [13]. Phosphorylated S6
and 4EBP1 enhance protein translation. In mTORC2,
mTOR occurs in a complex with Rictor (rapamycin-
insensitive companion of mTOR), mLST8, mSin1, protor,
Deptor and Hsp70 [14-17]. mTORC2 is primarily acti-
vated by growth factors, but the mechanism is largely
unknown. It has recently been suggested that mTORC2
activation is dependent on PI3-kinase, but independent
of Akt [18]. mTORC2 is able to phosphorylate Akt on
Ser473, at least in some cell types [19]. Other substrates
for mTORC2 include PKCα and paxillin [20]. mTOR can
be activated by growth factor signaling, such as by PDGF,
but the roles of mTORC1 and mTORC2 in PDGF-BB-
induced signal transduction have not been established.
The serine/threonine kinase Akt is activated by PDGF-
BB stimulation in a PI3-kinase-dependent manner. Acti-
vation of PI3-kinase generates PIP3 that can interact
with and thereby translocate Akt to the plasma
membrane, where it is activated by phosphorylation
on Ser473 in a hydrophobic motif and Thr308 in the
activation loop of the kinase domain [19,21,22]. Thr308
is phosphorylated by phosphoinositide-dependent protein
kinase 1 (PDK1), whereas several candidates, including
mTORC2, may perform the Ser473 phosphorylation
[19,23-25]. Furthermore, the kinase responsible for the
Ser473 phosphorylation may be different for different cell
and receptor types. When activated, Akt transduces
important survival signals that interfere with the apoptotic
process, for example by inhibition of Foxo, Bad and
caspase 9 [26-28].
Phoshoplipase Cγ catalyzes the hydrolysis of PIP2, thus
releasing the polar head group inositol-1,4,5-trisphosphate(IP3), while diacylglycerol (DAG) remains embedded in the
plasma membrane [29]. IP3 release results in mobilization
of Ca2+ from intracellular stores. Both DAG and Ca2+ par-
ticipate in the activation of protein kinase C (PKC) family
members, some of which require both DAG and Ca2+
(PKCα, β, γ), whereas others require only DAG (PKCδ, ε,
η, θ) [30]. In addition, there are atypical PKC isoforms
(PKCζ, ι) that are regulated by other means [31]. PLCγ is
activated by direct SH2-domain-dependent interaction
with activated tyrosine kinase receptors and subsequent
phosphorylation [32,33]. Another phospholipase that is
activated by receptor tyrosine kinases is phospholipase
D (PLD). PLD acts by hydrolyzing phosphatidylcholine
generating choline and phosphatidic acid [34] which is
required for mTORC1 activation by mitogenic factors [35].
Regulation of PLD activity is complex and has been
shown to involve small G-proteins, phosphatidylinositol
4,5-bisphosphate (PIP2), Ca
2+ and kinases [36]. PDGF
has been demonstrated to promote PLD tyrosine phos-
phorylation and activation by a mechanism involving
the production of reactive oxygen species [37].
In this study, we have explored the role of mTOR in the
regulation of PDGF-BB signaling. We found that Rictor,
and hence mTORC2, promotes the PDGF-BB-induced
phosphorylation of Akt at Ser473, as well as the phospho-
rylation of PLCγ1 and PKCα in addition to promoting
PKCα protein stability. Moreover, we show that PLD
activity is important for S6 phosphorylation and that this
occurs through mTORC1. However, our data suggest that
S6 phosphorylation downstream of PDGFR does not rely
on Akt activation. Functionally, mTOR inhibition by rapa-
mycin suppressed PDGF-BB-mediated cell proliferation,
whereas rapamycin treatment or the loss of Rictor in the
mTORC2 complex had no significant impact on the
chemotactic response toward PDGF-BB.
Results
Inhibition of mTORC2-Akt signaling does not influence
the phosphorylation of the ribosomal S6 protein
downstream of mTORC1
Initially, we investigated if mTORC1 and mTORC2
function downstream of PI3K using the selective pan
PI3K inhibitor NVP-BKM120, which in contrast to the
classical PI3K inhibitors wortmannin or LY29004 does
not inhibit mTOR [38]. NPV-BKM120 inhibited Akt
phosphorylation at both Ser473 and Thr308 and also
reduced mTOR and S6 phosphorylation upon PDGF-BB
stimulation (Figure 1A), indicating that PI3K is required
for activation of both mTOR complexes.
Previous studies have shown that Rictor is an essential
component of the mTORC2 complex, which induces
Akt phosphorylation at Ser473, at least in some cell
types [39]. To elucidate whether mTORC2 is also ne-
cessary for PDGF-BB-induced Akt phosphorylation in
Figure 1 PDGF-BB-mediated S6 phosphorylation does not require Akt phosphorylation. NIH3T3 cells (A, B, D) and Rictor-null MEFs (C)
were serum-starved for 24 h and then stimulated for indicated time periods with PDGF-BB (20 ng/ml) without or with pretreatment for 1 hours
(otherwise specified) in the presence of the inhibitors NPV-BKM120 (A), rapamycin (Rap, 10 nM) (B), or tricribine (20 μM) (D) for indicated time
periods. Total cell lysates (TCL) were prepared, and the levels of Akt phosphorylation at S473 and T308, as well as S6 phosphorylation and the
expression of total protein were assayed by immunoblotting (Ib). The relative protein phosphorylations were quantified for a representative
experiment.
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NIH3T3 cells, which has been shown to inhibit mTORC1
and 2, as well as Rictor-deficient cells. Using both
approaches, mTORC2 was found to be important for
PDGF-BB-induced phosphorylation of Akt on Ser473, but
not on Thr308 (Figure 1B & C), although prolonged rapa-
mycin treatment slightly reduced Thr308 phosphorylation.
In contrast, a short term treatment with rapamycin, which
only inhibits mTORC1, did not influence the PDGF-BB-
induced Akt phosphorylation (Figure 1B). However, the
levels of Rictor were not affected by rapamycin treatment
(Figure 1B).
There are reports suggesting that mTORC2-Akt can be
considered as upstream regulator of mTORC1 and its
downstream substrate S6 [40-42]. We investigated whether
this is the case using Rictor-null cells. As can be seen in
Figure 1C, no decrease in the PDGF-BB-induced S6 phos-
phorylation is seen in Rictor-deficient cells compared to
control cells, suggesting that mTORC2-Akt is not up-
stream of mTORC1-S6. In contrast, both short termtreatment with rapamycin (inhibits mTORC1), or long
term treatment (inhibits both mTORC1 and 2) efficiently
inhibited S6 phosphorylation, confirming the importance
of mTORC1 for its phosphorylation (Figure 1B). To further
confirm that Akt is not needed for S6 phosphorylation, we
used the Akt pathway inhibitor triciribine [43]. Triciribine
completely abolished the PDGF-BB-induced Akt phos-
phorylation, but did not influence S6 phosphorylation
(Figure 1D).
To conclude, mTORC2 is of major importance for Akt
Ser473 phosphorylation and the mTORC1-promoted
phosphorylation of S6 is not dependent on signaling
through the mTORC2-Akt pathway.
mTORC1-mediated phosphorylation of S6 depends
on PLD
PLD has been proposed to contribute to mTORC1 activity
by producing phosphatidic acid (PA) [35]. To investigate
the importance of PLD in the activation of mTORC1 and
2, we treated cells with 1-butanol which is a preferred
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PA. The secondary alcohol, 2-butanol, was used as a nega-
tive control since PLD cannot use it as a substrate.
As shown in Figure 2A, the ability of PDGF-BB to pro-
mote phosphorylation of the mTORC1 substrate S6 was
reduced in the presence of 1-butanol, but not in the pres-
ence of 2-butanol. Importantly, phosphorylation of Akt,
which is dependent on mTORC2, was not reduced by
1-butanol treatment (Figure 2A). Similar to NIH3T3 cells,
we also found that the 1-butanol treatment attenuates
S6 phosphorylation in Rictor null MEFs (Figure 1C).
Since PDGF-BB induces both Ca2+ influx and intracellu-
lar Ca2+ release [45], and it has been shown that Ca2+ can
regulate PLD activation [46], we investigated the impact of
Ca2+ chelators on PDGF-BB-induced S6 and Akt phos-
phorylation. We found that chelation of extracellular or
intracellular Ca2+ by EDTA and BAPTA, respectively, both
efficiently inhibited the phosphorylation of S6 consistent
with a role for Ca2+ in PLD activation or subsequent
mTORC1 activation (Figure 2B). Interestingly, we also
observed that the PDGF-BB-induced Akt phosphorylation
on Ser473 was inhibited by Ca2+ chelation (Figure 2B).
In summary, these finding indicate that PLD signaling
is necessary for PDGF-BB-induced phosphorylation of
S6 by mTORC1, and that Ca2+ is central for Akt phos-
phorylation on Ser473 in response to PDGF-BB.
PLC signaling is important for PDGF-BB-induced Akt
phosphorylation
To confirm our finding that Ca2+ is involved in regula-
tion of Akt phosphorylation on Ser473, we used domin-
ant negative PLCγ (dnPLCγ), and the low molecularFigure 2 PDGF-BB-mediated S6 phosphorylation is regulated by PLD/
serum-starved for 24 h and then stimulated for indicated time periods with
(1-B, 0.3%), 2-butanol (2-B, 0.3%), and Ca2+ chelators BAPTA-AM (BA, 10 μM
were prepared, and the levels of Akt phosphorylation at S473 and T308, S6
by immunoblotting (Ib). The relative protein phosphorylations were quantiweight inhibitor U73122, which inhibits both PLCγ and
PLD [47,48]. Consistent with the effect of Ca2+ chelation
(Figure 2B), U73122, as well as dnPLCγ inhibited Ser473
phosphorylation on Akt, however, no effect on the phos-
phorylation of Thr308 was found (Figure 3A & B). In
addition, U73122 also inhibited S6 phosphorylation, in
concurrence with the ability of this drug to inhibit PLD.
To further investigate the role of PLCγ signaling in Akt
activation, we used PLCγ1-null cells. Importantly, these
cells have been shown to also have a deficient PLD acti-
vation [49]. Using these cells, we observed a defect in
PDGF-BB-induced Akt phosphorylation on Ser473, but
also on Thr308 (Figure 3C). This surprising finding
suggests that phosphorylation of Akt on Ser473 is
dependent on PLCγ activity, whereas the phosphoryl-
ation on Thr308, which is not affected by PLC inhibition
or Ca2+ chelation, requires the presence of PLCγ1, but
not necessarily its activity. Previously, it has been shown
that inhibition of p38 signaling by SB203580 reduces
Akt phosphorylation [50]. This effect was not observed
in our experiment (Figure 3A).
Since PKC isoforms are activated downstream of
PLCγ, and it has been reported that mTORC2 regulates
the stability and phosphorylation of PKCα [51], we
investigated if the requirement of Ca2+ and PLCγ for
Akt phosphorylation occurred through activation of
PKC. First, we confirmed the previously reported reduc-
tion of PKCα levels in the Rictor-null cells (Figure 3D).
Next, we downregulated the PKC isoforms that are
dependent on diacylglycerol (DAG) for their activation, by
treating cells with PMA overnight. To monitor the effect
of PMA treatment, we investigated phosphorylation ofCa2+ signaling. NIH3T3 cells (A, B) and Rictor-null MEFs (C) were
PDGF-BB (20 ng/ml) with or without pretreatment with 1-butanol
) or EDTA (ED, 2 mM) for 30 min, as indicated. Total cell lysates (TCL)
phosphorylation, as well as the total protein expression, were assayed
fied for a representative experiment.
Figure 3 PDGF-BB-induced Akt phosphorylation involves the PLC/PKC pathway. NIH3T3 cells (A and E), dnPLCγ PAE cells (B), PLCγ-null (C)
and Rictor null (D and F) MEFs were serum-starved for 24 h and then stimulated with PDGF-BB (20 ng/ml) with or without pretreatment with the
inhibitor U73122 (5 μM) and SB203580 (10 μM) for 1 h, or with or without PMA (1 μM) for 24 h, as indicated. Akt phosphorylation level at S473
and T308, as well as mTOR, S6, PLCγ, PKCα and pMarcks phsphorylation and the total protein expression were assayed by immunoblotting (Ib) of
total cell lysate. β-actin immunoblotting served as a loading control. The relative protein phosphorylations were quantified for a representative
experiment.
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known PKC substrate (Figure 3E). In cells with downre-
gulated PKC isoforms, we observed a partial reduction in
the ability of PDGF-BB to promote Akt phosphorylation
(Figure 3E). Consistent with our previous experiments, we
found that S6 phosphorylation was independent of the
reduction in Akt phosphorylation (Figure 3E).
The activity of PLCγ has been connected to its phos-
phorylation on Tyr783 [52]. To see if the absence of
Rictor (and thus mTORC2) affects PLCγ function, we
analyzed the ability of PDGF-BB to stimulate PLCγ
phosphorylation. Surprisingly, we found that in Rictor-
null cells the PLCγ phosphorylation was abolished and
similar to what was seen for PKCα, the total protein
level was slightly reduced (Figure 3F). The mechanism
for the reduced PLCγ protein level is unclear, but in the
case of PKCα it has been demonstrated that mTOR-mediated phosphorylation is important for protein sta-
bility [53].
To conclude, inhibition of PLCγ or Ca2+ chelation
resulted in decreased PDGF-BB-induced phosphory-
lation of Akt on Ser473, but did not affect phosphory-
lation on Thr308. In contrast, the presence of PLCγ
protein was needed for the phosphorylation on Thr308.
Furthermore, we found that Rictor-null cells, which have
defective PDGF-BB-induced Akt Ser473 phosphory-
lation, are impaired in PLCγ/PKCα signaling. However,
treatment overnight with PMA inhibited Akt phospho-
rylation on both Ser473 and Thr308. These findings
suggest that Thr308 is phosphorylated by a kinase that is
downregulated by PMA treatment and thus normally
regulated by DAG, possibly a novel PKC isoforms that
requires DAG but not Ca2+. Overnight treatment with
PMA did not affect PDK-1 phosphorylation and neither
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phosphorylation of Akt on Ser473 is dependent on
PLCγ1 activity, Ca2+, DAG and the conventional PKCs.
PDGF-BB-induced Erk1/2 MAP-kinase signaling is
important for the kinetics of S6 phosphorylation
In addition to Akt, MAP kinase pathways have been
linked to mTOR signaling [54]. We found that the
selective Mek1/2 inhibitor CI-1040 completely blocked
Erk1/2 phosphorylation and reduced S6 phosphory-
lation, primarily after 15 min of stimulation, but had no
effect on Akt phosphorylation (Figure 4A). Thus, Erk1/2Figure 4 PDGF-BB-induced Erk1/2 signalling affects the kinetics of S6
MEFs (C) were serum-starved for 24 h and then stimulated with PDGF-BB (2
rapamycin (10 nM) for 1 h, 1-butanol (1-B, 0.3%), 2-butanol (2-B, 0.3%), BAP
as indicated. The levels of phosphorylation of Erk1/2, mTOR, Akt and S6, as
cell lysates.may contribute to mTORC1 activation at early stages of
signaling, as previously noted [54]. To further clarify the
role of Erk1/2 in mTORC1 signaling after prolonged
PDGF-BB treatment, we performed a time-course
experiment stimulating cells for up to 4 h (Figure 4B).
We found that only the rapid, initial induction of S6
phosphorylation was inhibited by CI-1040, whereas the
S6 phosphorylation reached almost the same level in
cells treated with CI-1040 as in vehicle treated cells after
longer time periods of PDGF-BB stimulation (Figure 4B).
The PDGF-BB-induced Erk1/2 phosphorylation was
not dependent on mTORC2 (Figure 4C), mTORC1phosphorylation. NIH3T3 cells (A, B, D, E, F and G) and Rictor-null
0 ng/ml) in the absence or presence of CI-1040 (0.5 μM) and
TA-AM (10 μM) and EDTA (2 mM) for 30 min, and PMA (1 μM) for 24 h,
well as the total protein, were assayed by immunoblotting (Ib) of total
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(Figure 4G).
In summary, PDGF-BB-induced Erk1/2 activity is only
important for the early onset of mTORC1-mediated
phosphorylation of S6. Furthermore, neither mTORC1
nor mTORC2 are needed for PDGF-BB-induced Erk1/2
activation.
Role of mTOR signaling in PDGF-BB-induced cellular
responses
Next, we wanted to elucidate the functional conse-
quences of interfering with mTOR signaling for PDGF-
BB-mediated cellular responses, i.e. survival, migration
and proliferation. To this end, we used the Rictor-null
cells which lack a functional mTORC2 complex, as well
as long term treatment (24 h) with rapamycin to inhibit
both mTORC1 and 2. We found that serum starvation
induced caspase-3 cleavage, which could be rescued by
addition of PDGF-BB in control cells, but not in Rictor
null cells, suggesting a role of mTORC2 in promoting
cell survival in response to PDGF-BB (Figure 5A). In ac-
cordance with a recent report [55] we could confirm
that Rictor-null cells have increased rate of apoptosis
compared to control MEFs (Figure 5B). Interestingly, in
these cells the apoptosis could not be modulated by
either serum levels or addition of PDGF, despite the
reduction of caspase 3 cleavage observed in control
MEFs in the presence of PDGF. The reasons of these
findings remain to be elucidated.
In contrast, the migratory response was not affected
by loss of the mTORC2 complex (Figure 5C). As
expected, downregulation of both mTORC1 and 2 by
rapamycin strongly inhibited PDGF-BB-promoted DNA
synthesis in NIH3T3 cells (Figure 5D). Unfortunately,
we were not able to analyze the proliferation of Rictor-
null cells in response to PDGF-BB, since neither control
nor knock-out cells responded to PDGF-BB in the prolif-
eration assay (data not shown). Furthermore, long term
treatment with rapamycin did not affect the PDGF-BB-
induced migration of NIH3T3 cells (Figure 5E).
In conclusion, PDGF-BB signaling through mTORC2
is important for the ability of PDGF-BB to suppress
starvation-induced cleavage of caspase 3, but not for
chemotaxis. Complete inhibition of mTOR signaling by
rapamycin abolished the ability of PDGF-BB to promote
cell proliferation.
Discussion
Akt is an important kinase mediating survival signaling,
which is regulated by phosphorylation on Thr308 by
PDK1 and on Ser473 by several other kinases. A large
number of kinases have been proposed to perform the
Ser473 phosphorylation [56]. In the present study, we
showed that phosphorylation of Akt on Ser473 inresponse to PDGF-BB was critically dependent on the
mTORC2 complex since the phosphorylation was strongly
repressed in Rictor-null cells. Consistently, prolonged
treatment with rapamycin that downregulates both
mTORC1 and 2, inhibited the PDGF-BB-induced phos-
phorylation on Ser473, whereas short term rapamycin
treatment which only inhibits mTORC1, did not. Further-
more, we also found that U73122, which blocks both PLC
and PLD activities, as well as Ca2+ chelating agents, inhib-
ited the PDGF-BB-mediated phosphorylation of Akt on
Ser473, but not on Thr308. It has been reported, and we
confirmed, that in Rictor-null cells the level of PKCα is
severely reduced [51]. In addition, we found that PLCγ
phosphorylation is dramatically suppressed in Rictor null
cells compared to control cells. Interestingly, treatment
with PMA overnight to downregulate DAG-dependent
PKC isoforms resulted in inhibition of phosphorylation of
Akt on both Ser473 and Thr308. The effect on Thr308
did not occur by any reduction in p-PDK1 levels, indicat-
ing that a DAG responsive kinase is involved in the phos-
phorylation of Thr308. Another possibility is that while
PMA treatment overnight did not affect the phosphoryl-
ation of PDK1, it may have influenced its intracellular
localization. We also found that in PLCγ1 null cells, the
phosphorylation of both Ser473 and Thr308 on Akt were
reduced. Interestingly, it has recently been demonstrated
that PDK1 and PLCγ interact after EGF stimulation and
that PDK1 is involved in the activation of PLCγ in a man-
ner that only partially depends on PDK1 activity [57].
Thus, it is possible that the interaction between PDK1 and
PLCγ regulates the ability of PDK1 to phosphorylate Akt
on Thr308, potentially by acting as a scaffold. This
hypothesis is consistent with our observation that PDGF-
BB-induced Thr308 phosphorylation is reduced in PLCγ
deficient cells but is not affected by PLCγ inhibition or
Ca2+ chelation.
Collectively, these results suggest that the pathway
leading from the PDGFR to phosphorylation of Akt
involves mTORC2 and PLC/Ca2+ signaling, although
some aspects of the molecular mechanism remain to be
elucidated. Activation of Akt has been associated with
increased cell viability [58]. Consistent with a critical
role for mTORC2 in Akt activation, we found that in
Rictor-deficient cells, which are blunted in their ability
to activate Akt, PDGF-BB was not able to suppress
starvation-induced caspase-3 cleavage, whereas it did so
in control cells.
mTORC1 is widely accepted to be responsible for
S6-kinase activation leading to phosphorylation of the
ribosomal S6 protein, thus facilitating protein transla-
tion. Several reports have suggested that mTORC1 may
be downstream of Akt signaling [13], although this has
been challenged [59]. Our results suggest that in PDGF-
BB-stimulated fibroblasts, Akt is not upstream of S6
Figure 5 (See legend on next page.)
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Figure 5 Effect of mTOR signaling on caspase 3 cleavage, apoptosis, migration and proliferation upon PDGF-BB stimulation. Rictor-null
or control MEFs were serum-starved for 24 h and then treated with PDGF-BB for 24 h; activation of caspase 3 was measured thereafter by
immunoblotting against cleaved caspase 3 (A). Internucleosomal DNA fragmentation was quantitatively determined by assaying for cytoplasmic
mononucleosome- and oligonucleosome-associated histone accumulated in apoptotic cell (B), data represent three separate experiments each
performed in duplicate ± SEM. Cell migration experiments were carried out in a 96-well ChemoTX cell migration microplate. The wells of the
microplate were filled with medium containing combinations of PDGF-BB with Rictor-null or control MEFs (C), as well as NIH3T3 cells with or
without longterm treatment with rapamycin (E), as indicated. The amounts of migrated cells are given as index units; data represent three
separate experiments, each performed in quadruplicates ± SEM. In separate experiments, NIH3T3 cells were serum-starved and then stimulated for
24 h with PDGF-BB in medium containing [3H] thymidine. The fold increase of PDGF-induced [3H]thymidine incorporation over the respective
positive control values is shown. Values are means ± S.E of three independent experiments each performed in triplicate. Statistical significant
differences (Students T-test) are indicated by *P < .05 compared with unstimulated or control cells (B & D).
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Akt phosphorylation on Ser473 is reduced, S6 phosphor-
ylation was normal. Moreover, treating cells with the
Akt pathway inhibitor triciribine completely abolished
Akt phosphorylation, but had no impact on PDGF-BB
promoted S6 phosphorylation. This is consistent with a
study in Drosophila showing that Akt phosphorylation
of TSC2 is not required for mTOR activation [60], but
in contrast to studies on insulin signaling, where it was
shown that Akt phosphorylation of TSC2 is necessary
for mTORC1 activation [9].
We observed inhibition of S6 phosphorylation after
treatment with Ca2+ chelators. A possible Ca2+-dependent
pathway from the PDGFR to mTORC1 involves PLD. PLD
degrades phosphatidylcholine into choline and phosphati-
dic acid. Phosphatidic acid have been shown to bind to
mTOR and activate mTORC1 [35]. Treatment of cells with
the PLD inhibitor 1-butanol suppressed the PDGF-BB-
induced S6 phosphorylation, without affecting Akt phos-
phorylation. As expected, the PLC/PLD inhibitor U73122
also suppressed S6 phosphorylation. It is possible that
PLCγ contributes to PLD activation by causing increased
Ca2+ levels, since PLD requires Ca2+ for its activity [61]. In
support of this notion, it has been reported that in PLCγ-
deficient cells, PLD signaling is reduced and this may
explain the observed reduction in S6 phosphorylation in
PLCγ1−/− cells. Analogous to Akt activation where both
mTORC2 and PDK1 phosphorylation are required for full
Akt activation, mTORC1 has been proposed to collaborate
with PDK1 in S6 kinase activation [62].
Erk1/2 MAP-kinases are activated by most receptor
tyrosine kinases and have been shown to regulate prolif-
eration as well as protein translation [63]. mTOR is also
involved in these processes, and there are reports impli-
cating a link between Erk1/2 and mTOR signaling. In
particular, it has been shown that Erk1/2 can directly
phosphorylate Raptor and as a consequence activate
mTORC1 [64]. In addition, both Erk1/2 and the down-
stream p90 ribosomal S6 kinase can phosphorylate the
TSC1/2 complex resulting in mTORC1 activation [65].
To explore whether Erk1/2 is involved in PDGF-BB-
induced mTOR signaling, we investigated the effect ofthe selective MEK1/2 inhibitor CI-1040 on Akt and S6
phosphorylation. Inhibition of the Erk1/2 pathway did
not influence the PDGF-BB-induced phosphorylation of
Akt, however, it delayed the onset of S6 phosphorylation.
Conversely, interfering with mTOR signaling did not sig-
nificantly affect the PDGF-BB-induced Erk1/2 phosphor-
ylation. Thus, signaling through the Erk1/2 pathway is
not critical for mTORC2 activity, but is required for the
initial rapid onset of mTORC1. The S6 phosphorylation
observed after prolonged PDGF-BB treatment was not
dependent on Erk1/2 signaling. Furthermore, it has been
proposed that inhibition of mTOR-dependent signaling
by rapamycin leads to an increased Erk1/2 activity and
potentiation of PDGF-induced Erk1/2 phosphorylation
[66]. In contrast to these findings, we observed that nei-
ther interfering with mTOR signaling using Rictor-null
cells, short or long term treatment of NIH3T3 cells with
rapamycin and PLD inhibition, nor Ca2+ chelation
affected PDGF-BB-induced Erk1/2 phosphorylation.
Signaling through mTOR has been reported to regulate
both proliferation and migration [13,67]. A commonly
used inhibitor of mTOR is rapamycin. However, the two
mTOR containing complexes, mTORC1 and mTORC2,
have different sensitivities to rapamycin. mTORC1 is
rapidly inhibited whereas mTORC2 requires prolonged
rapamycin treatment; thus, short term (1 h) treatment
with rapamycin only inhibits mTORC1 whereas long term
(24 h) treatment also inhibit mTORC2. Treating cells for
extended time periods with rapamycin abolished the mito-
genic effect of PDGF-BB, suggesting that functional
mTOR signaling is required for cell proliferation. In con-
trast, Rictor-deficient cells showed a similar chemotactic
response as control cells towards PDGF-BB, indicating
that mTORC2 is not involved in PDGF-BB-dependent cell
migration; this is surprising since mTORC2 has been
shown to regulate cell polarity and the dynamics of the
actin cytoskeleton [68], although no alterations in the
actin cytoskeleton were observed in Rictor-null MEFs
[51,59]. Similarly, inhibition of mTORC1 and 2 in
NIH3T3 cells did not influence the chemotactic properties
of these cells. mTORC2 may affect cell migration by pro-
moting PKCα-dependent phosphorylation of the focal
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ously been found that PDGF-BB can promote paxillin
phosphorylation through the JNK MAP kinase pathway
[69], and this may relieve the absolute requirement of
mTORC2 in PDGF-BB-mediated fibroblast migration.
Conclusions
The pathway from PDGFR leading to phosphorylation of
Akt involves both the mTORC2 and PLCγ/PKC path-
ways. In contrast, phosphorylation of S6 downstream of
mTORC1 depends on PLD activation, but is independ-
ent of mTORC2 and Akt signaling (Figure 6). During
conditions where Erk1/2 signaling is inhibited, the initial
S6 phosphorylation is delayed. Interfering with mTOR
signaling did not affect PDGF-BB-induced Erk1/2 phos-
phorylation. Functionally, inhibition of mTORC1 and 2
by rapamycin effectively blocked PDGF-BB-mediated
cell proliferation. Figure 6 depicts a schematic figure of
key roles of mTOR in PDGF-BB-induced cell signaling.
Materials and methods
Reagents
Recombinant human PDGF-BB was generously provided
by Amgen (Thousand Oaks, CA). The inhibitors CI-
1040 (PD184352), triciribine and NVP-BKM120 were
from Calbiochem (San Diego, CA), Cayman Chemical
Company (Michigan, USA) and Selleckchem (Houston,
USA), respectively. Antibodies against phosphorylated
Akt (#9271), phosphorylated mTOR (#5536), phosphory-
lated S6 (#4858), cleaved caspase 3 (#9661), phosphory-
lated Erk1/2 (#9106) and phospho-MARCKS (#2741)
were purchased from Cell Signaling Technology (Bev-
erly, MA). A β-actin antibody was purchased from SigmaFigure 6 Schematic representation of PDGF-BB-mediated
regulation of Akt and S6. Initially, PDGF-BB-mediated activation of
Akt involves both mTORC2 and the PLCγ/PKC pathways. Activation
of S6 downstream of mTORC1 depends on PLD activation,
independent of mTORC2 and Akt signaling. Ca2+ is required for
regulation of Akt and S6 activity.(St. Louis, MI). A rabbit antiserum recognizing Erk was
raised against a peptide corresponding to the carboxyl-
terminal sequence EETARFQPGYRS conjugated to KLH.
The wild-type control and Rictor-knockout mouse em-
bryonic fibroblasts (MEFs) have been described previously
[59] and were kindly provided by Dr Mark Magnuson
(Vanderbilt University School of Medicine, Nashville, TN,
U.S.A.). PLCγ1-null MEFs have been described previously
[70] and were kindly provided by Dr Matilda Katan
(Institute for Cancer Research, London, UK).Cell culture
The murine embryonic fibroblast cell line NIH3T3, and
MEFs were cultured in Dulbecco's modified Eagle's
medium (DMEM) with 10% bovine serum, 100 U/ml
penicillin and 100 μg/ml streptomycin. For serum-star-
vation, cells were washed once and incubated in medium
containing 0.1% FBS. Lipase inactive PLC-γ1 H335F/
H380F (dnPLCγ), porcine aortic endothelial (PAE) cells
were cultured in Ham’s F-12 containing 10% bovine
serum albumin, in the presence or absence of 20 ng/ml
doxycycline to induce protein expression [71].Immunoblotting
Subconfluent cells were starved and incubated with ve-
hicle or inhibitors at the indicated concentrations and
thereafter stimulated with PDGF-BB (20 ng/ml, or as
specified) for the indicated periods of time. Cells were
washed two times in ice-cold phosphate-buffered saline
and lysed in 20 mM Tris pH 7.4, 150 mM NaCl, 5 mM
EDTA, 1% Triton X-100, 0.1% SDS, 1% deoxycholate,
1 mM Pefa Bloc and 1 mM sodium orthovanadate.
Extracts were clarified by centrifugation, and protein
concentration was determined by the BCA protein assay
(Pierce). Equal amounts of lysates were boiled with SDS
sample buffer containing dithiothreitol. Proteins were
separated by SDS-PAGE and then electro-transferred to
polyvinylidene difluoride membranes (Immobilon P),
which were blocked in 5% bovine serum albumin or 5%
milk in Tris-buffered saline solution containing 0.1%
Tween-20. Primary antibodies were diluted according to
the manufacturer’s instructions and membranes incu-
bated overnight at 4°C. After washing, the membranes
were incubated with horseradish peroxidase-conjugated
anti-rabbit or anti-mouse IgG antibodies (both from
Amersham Biosciences), and proteins were visualized
using ECL immunoblotting detection systems from
Roche Applied Science on a cooled charge-coupled
device (CCD) camera (Fuji, Minami-Ashigata, Japan).
Densitometrical analysis of the immunoblots was per-
formed using advanced image data analyzer (AIDA) soft-
ware (Fujifilm).
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Control and Rictor-null MEFs were starved for 24 h,
then the extent of apoptosis was determined by quantifi-
cation of nucleosomes released into the cytoplasma
using the Cell Death Detection ELISA Plus kit (Roche
Applied Science) according to the manufacturer's direc-
tions. In the separate experiments the level of caspase-
3-cleaved fragments was analyzed by immunoblotting.
[3H]thymidine incorporation assay
For thymidine incorporation assay subconfluent cell
cultures were serum-starved in 24-well plates and then
incubated for 24 h in the presence or absence of rapa-
mycin with PDGF-BB in DMEM containing [3H]thymi-
dine (0.1 μCi/ml). Incorporation of 3H-radioactivity into
acid-insoluble material was measured by a scintillation
counter. The obtained count per minute values in tri-
plicate was normalized against the positive control of
cultures incubated in 10% bovine serum for each
experiment.
Cell migration assays
Cell migration was determined as previously described [69].
In brief, 96-well ChemoTX (Neuroprobe, Gaithersburg,
MD) cell migration microplate filters were coated with
50 μg/ml fibronectin (BD Biochemicals, Erembodegem,
Belgium) for 1 h at room temperature. Control and Rictor
null-MEFs, or NIH3T3 cells treated with or without rapa-
mycin, were serum-starved overnight and then trypsinized
into single cells. The wells of the ChemoTX microplate
were filled with DMEM containing the indicated PDGF-BB
concentrations. The filters were placed in the wells and
50,000 cells were added on top of each filter. The chamber
was incubated for 4 h at 37°C, 5% CO2. Cells adhering to
the bottom of the filter were fixed by a 3-min incubation
in 96% ethanol. The adherent cells were stained with
Giemsa (Sigma)-and the migration indices were assessed
by scanning the filter in a CCD camera (Fuji). Quan-
tifications were performed using Aida Image Analyzer
software. All experiments were performed in quadru-
plicate, and single representative data of three separate
experiments ± SD are shown.
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